PARTNER 3 Trial1

PARTNER 3 — A large randomised, prospective, multi-centre trial showing superior outcomes for transcatheter aortic valve implantation (TAVI) compared to surgery (SAVR) in low-surgical-risk patients.1

Title slide from PARTNER 3. A large prospective, multi-centre trial showing superior outcomes for TAVI compared to surgery (SAVR) in low-risk patients

The primary endpoint of reduced death, stroke or CV rehospitalisation was maintained over a 2yr follow-up.2

See the latest follow-up results
Title slide from Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

The original trial report showed TAVI met both the primary endpoint as well as a number of prespecified secondary endpoints vs SAVR.1

Access the original 1yr data
Title slide from Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Patients with severe aortic stenosis at Low Surgical Risk

The disease-specific health status improvements for TAVI compared to SAVR were demonstrated not just at 1 month but also at 6 and 12 months.3

Read the QoL data

PARTNER II Trial4

PARTNER II Trial showed comparable outcomes for Edwards SAPIEN 3 TAVI vs SAVR in intermediate-risk patients.

Continuing to support TAVI as a viable alternative to SAVR with comparable clinical and durability outcomes

Subsequent subgroup analysis of PARTNER II Trial has provided further insight into the role of TAVI

PARTNER 1A Trial5

Female interventional cardiologist reassures her patient with a hand on his shoulder

TAVI showed similar outcomes compared to SAVR in high surgical risk patients (PARTNER 1A).

Read the initial 1yr follow up Find out the subsequent 5yr follow up data

PARTNER 1B Trial6

Smiling male patient in his 80s

The first PARTNER Trial. It demonstrated superior clinical outcomes for TAVI vs standard therapy in sAS patients deemed inoperable.

Read the initial 1yr follow up Discover the subsequent 5yr follow up
Four cardiology doctors in scrubs concetrating in the cath lab

Keep up to date with the latest TAVI developments and research

See clinical summaries

Stay informed with our newsletter

References:

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705 (plus Supplementary Appendix).
2. Mack MJ, Leon MB. Two Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low-Risk Randomised Trial. Presented at ACC.20. Chicago March 2020.
3. Baron SJ, Magnuson EA, Lu M, et al. Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Low Surgical Risk. J Am Coll Cardiol. 2019;74(23):‍2833-2842.
4. Leon MB, Smith CR, Mack MJ, et al. N Engl J Med. 2016;374:1609–1620 and supplementary material.
5. Smith CR, Leon MB, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98.
6. Leon MB, Smith CR, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-607.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

PP--EU-3364 v1.0